or can it be separate? a doctor said that a persons genital warts is just genital warts and NOT HPV, is this possible?
are all genital warts hpv? and if genital warts can be JUST genital warts unrelated to HPV then do they still cause cervical or other kinds of cancer?

Actually, l got no idea what ur doctor is talking about!

perhaps s/he is traying to tell u that there r strains of HPV that cause genital warts & there r other strains of HPV that cause cervical cancer.

but no, genital warts, as defined by medical dictionaries, is caused by some strains of HPV. As wikipedia defines them: They can be caused by strains 6, 11, 30, 42, 43, 44, 45, 51, 52 & 54 of genital HPV; types 6 & 11 r responsible for 90% of genital warts cases.

Yes genital warts r on the genital HPV type.
All warts anywhere on the body r one of the 100+ HPV (human Papilloma virus) types.
They r about 40 genital HPV types that r considered SDI’s because they r transmitted most often through sex. They r 15 high risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82) that r considered high risk HPV types these r the HPV that might persist & progress to cancer if left untreated. These 15 high risk HPV types r found in anal cancer, vulva & vaginal cancer…and oral cancers.
Visible Genital warts r usually low risk HPV types 6 or 11. These HPV types r not usually found cancers…but people with visible genital HPV types may also carry a co-infection with high risk HPV types. Low risk HPV types can cause abnormal cell changes of the cervix….but low risk HPV types usually regress faster than high risk HPV types. Other low risk HPV types r 40, 42, 43, 44, 54, 61, 70, 72, & 81
This link will tell u more about all warts that affect the body & the HPV types that affect the area.
http://emedicine.com/med/TOPIC1037.HTM

Genital Warts
http://emedicine.com/emerg/TOPIC640.HTM

Genital warts
Condylomata bearing HPV-6 or -11 have identical clinical
manifestations & histology [2]. Recent studies have shown that about
100% of GWs r caused by either HPV-6 or -11 but that 20–50% of
lesions also contain co-infections with HR HPV types [3] & [4]. GWs
do not usually result in major morbidity or mortality, but cause
significant psychological morbidity & very substantial healthcare
costs. Occasionally GWs persist for long periods of time and, rarely,
such long-standing lesions may progress to malignancy. GWs r highly
infectious, with a transmission rate of about 65% within sexual
partnerships from an infected to a susceptible sexual partner, & an
incubation period of between 3 weeks & 8 months, with the majority
developing warts at around 2–3 months [3]. Once GWs have developed,
they may show minimal change over time, become more numerous or
larger, or regress spontaneously. The majority of placebo-controlled
GW therapy trials show low rates of regression (around 5% complete
clearance) in the short term, although in one study over 16 weeks 20%
of women & 5% of men using placebo completely cleared their warts,
and 38% of women & 22% of men using placebo cleared over 50% of
their baseline warts [3]. Regressing warts contain significantly more
CD4 positive T cells, both within the stroma underlying the lesions
and the condylomata themselves, & greater expression of activation
markers [3]. There is no report of the rate of spontaneous regression
that may occur in the longer term. Following GW clearance with
therapy, recurrence is common & is often seen within 3 months in 25%
of cases, although rates of up to 67% have been observed [3]. In
clinical practice recurrences r often seen at sites of previous
lesions, & in these cases HPV infection in stem cells or
slow-turnover cells at the site of previous clearance has persisted
and then reactivated. The proportion of HPV-6/11 infections that are
either completely cleared or persist in a latent form after clinical
resolution is unknown, and, indeed, animal models suggest that both
outcomes can occur [3].
HPV-6/11 as a cause of cervical neoplasia
HPV-6 & -11 r frequently associated with LSIL. A recent
meta-analysis of 55 studies reported HPV-6 to be present in 8.1% of
HPV-positive LSIL cases & HPV-11 in 3.2% of cases [25]. However, it
remains unclear in what proportion of these HPV-6/11-positive LSIL
cases there is concomitant co-infection with a HR type, & whether
such HR co-infections would be ''minority passenger'' infections as
described in GWs, or represent true multiple-morphology cervical lesions.

Costs of HPV-6/11 disease
The principal healthcare costs caused by HPV-6/11 r through GWs and
RRP. Recent UK- & USA-specific data on the costs of treatment of GWs
in routine clinical practice [38] & [39] estimated the cost of a
single successful episode of treatment of a case of GWs to be £216 ($
377) in the UK & $ 436 in the USA. Using the UK ST l clinic 2004 GWs
prevalence data, this equates to around £31 million ($ 54 million) per
annum for the UK. One study from the USA estimated the annual direct
healthcare costs of GWs as $ 200 million [40]. In a report from the
Task Force on RRP, the annual cost for surgical procedures in the USA
was estimated to be $ 109 million for JORRP & $ 42 million for AORRP
[27]. In countries with cervical screening programmes there will also
be significant costs associated with HPV-6/11-associated abnormal
cytology & consequent procedures, although estimates of these costs
are not available.


http://sciencedirect.com/